Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
暂无分享,去创建一个
A. Vivancos | E. Aranda | A. Fernández Montes | B. Graña | J. C. Méndez | J. De la camara | M. Covela | E. Élez | N. Martínez | P. Gonzalez | M. Covela | A. Cousillas
[1] E. Oki,et al. O-21 METABEAM study: Combined analysis of concordance studies between liquid and tissue biopsies for RAS mutations in colorectal cancer patients with single metastatic sites , 2020 .
[2] S. Kopetz,et al. NeoRAS: Incidence of RAS reversion from RAS mutated to RAS wild type. , 2020 .
[3] A. Vivancos,et al. Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples , 2019, Scientific Reports.
[4] N. Pavlidis,et al. The Developing Story of Predictive Biomarkers in Colorectal Cancer , 2019, Journal of personalized medicine.
[5] G. Giannini,et al. Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer , 2019, Cancers.
[6] I. Zlobec,et al. Tumor Heterogeneity in Primary Colorectal Cancer and Corresponding Metastases. Does the Apple Fall Far From the Tree? , 2018, Front. Med..
[7] A. Bardelli,et al. Integrating liquid biopsies into the management of cancer , 2017, Nature Reviews Clinical Oncology.
[8] G. Pentheroudakis,et al. Current and future biomarkers in colorectal cancer , 2017, Annals of gastroenterology.
[9] O. Abdel-Wahab,et al. Genetic drivers of vulnerability and resistance in relapsed acute lymphoblastic leukemia , 2016, Proceedings of the National Academy of Sciences.
[10] M. Loh,et al. Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia , 2016, Proceedings of the National Academy of Sciences.
[11] J Ricke,et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] Aleksandra Markovets,et al. Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M , 2015, Nature Medicine.
[13] N. Normanno,et al. RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.